Baird Adds Senior Biotech Analyst Brian Skorney
MILWAUKEE, Jan. 7, 2013
Baird, an employee-owned, international capital markets, private equity, wealth and asset management firm, today announced that it has added Brian Skorney as a Senior Analyst in equity research. Skorney joins fellow Senior Analyst Chris Raymond in covering Biotechnology.
Skorney, based in New York City, initiated coverage on four biotech companies including Achillion Pharmaceuticals Inc. (ACHN)
, Cubist Pharmaceuticals, Inc. (CBST), Gilead Sciences, Inc. (GILD)
and InterMune, Inc. (ITMN).
“Brian’s sector knowledge is a valuable complement to Baird’s already successful Biotechnology coverage,” said Jon Langenfeld, Director of Equity Research. “Brian’s addition extends our underlying commitment to our Equity Capital Markets Healthcare franchise.”
In addition to the firm’s broad Healthcare/Life Science research investment, Baird has a full complement of Capital Markets, Sales, Trading and Strategic Advisory Healthcare specialists proving comprehensive worldwide investment banking services to all segments of the healthcare industry.
Brian Skorney, CFA Biography
Brian Skorney is one of Baird’s senior analysts covering Biotechnology. Skorney has followed the sector for six years, most recently at Brean Murray Carret & Co. Prior to his career in equity research, Skorney worked in medical research. Skorney received a B.S. in Biological Sciences from The University of Notre Dame and an MBA in Finance from The Stern School of Business at New York University.
About Baird’s Equity Research Team
Baird’s Equity Research Department consists of over 120 research professionals covering more than 690 companies. Baird analysts have been recognized repeatedly in The Wall Street Journal’s
annual “Best on the Street” survey and in StarMine’s
annual top analyst rankings. In 2012, Baird was awarded a No. 1 ranking by Greenwich Associates for U.S. Small- and Mid-Cap Equities for Most Trusted Research, Analyst Service and Sales Quality. The April 2012 Greenwich Associates U.S. Equity Investors-Small/Mid-Cap Funds survey was conducted with 94 U.S. small-cap and mid-cap fund managers. Rankings were based on the top ten research firms in the survey.
Baird is an employee-owned, international wealth management, capital markets, private equity and asset management firm with offices in the United States, Europe and Asia. Established in 1919, Baird has more than 2,700 associates serving the needs of individual, corporate, institutional and municipal clients. Baird has nearly $97 billion in client assets. Committed to being a great place to work, Baird ranked No. 21 on FORTUNE’s 100 Best Companies to Work For in 2012 – its ninth consecutive year on the list. Baird’s principal operating subsidiaries are Robert W. Baird & Co. in the United States and Robert W. Baird Group Ltd. in Europe. Baird also has an operating subsidiary in Asia supporting Baird’s investment banking and private equity operations. For more information, please visit Baird’s Web site at rwbaird.com.